International
Among participants with early symptomatic Alzheimer's disease, donanemab treatment significantly slowed clinical progression of the disease at 76 weeks, according to an international study. Donanemab is an antibody designed to clear brain amyloid plaque, which is hypothesised to play a role in Alzheimer's disease. The researchers conducted a randomized clinical trial of 1736 participants between 60 and 85 years of age with early symptomatic Alzheimer's disease and amyloid and tau pathology, with participants randomly assigned either a donanemab treatment or placebo every 4 weeks for 72 weeks. In people with the lowest levels of amyloid and tau pathology, the drug was able to slow Alzheimer's disease progression by 35%, while across the whole study group there was a 22% slowdown in disease progression. The AusSMC did an expert reaction on these results when they were first announced by the company prior to peer review.
From:
Sign In
